“This innovation was born out of deep research into consumer lifestyle needs and fits our future-forward approach to caring for human sight,” said Xiao-Yu Song, global head of R&D for Johnson & Johnson Vision said in a statement.
“ACUVUE OASYS with Transitions creates and defines an entirely new category of contact lenses that will address unmet needs for patients. After more than a decade of product development and numerous clinical trials involving more than 1,000 patients, we are excited to bring to market a solution to help contact lenses wearers manage the changing light conditions they face every day in their modern, active lives,” she added.
A range of everyday lighting situations, from artificial light to UV rays, can negatively impact eye comfort, vision and health.1,2,3 Some people compensate for these harsh lighting environments by squinting, shielding their eyes, or dimming lights. ACUVUE OASYS with Transitions automatically adapt, helping the human eye manage different types of light and varying intensities of brightness throughout the day.
This strategic partnership between Johnson & Johnson Vision (JJV) and Transitions Optical combines the respective strengths of each company. While ACUVUE is the world leader in contact lenses, Transitions Optical is the leading provider of photochromic (smart adaptive) lenses world wide. The two companies are working together to research and deliver best-in-class vision care innovations.
ACUVUE OASYS with Transitions has received 510(k) clearance from the U.S. Food and Drug Administration and is indicated for the attenuation of bright light. This regulatory milestone is an important step toward achieving JJV’s vision of helping people see better, connect better, and live better. The two-week reusable, spherical contact lens will be marketed by Johnson & Johnson Vision Care, Inc. and will be commercially available in first half of 2019.